Compounds for the treatment of cancer and inflammatory diseases

A method of treating a subject with a condition associated with Bruton's Tyrosine Kinase (“BTK”) comprising administering an effective amount of a compound of Formula I:

• or pharmaceutically acceptable salt, solvate, or tautomer thereof wherein:
• X1 and X2 are independently selected from O, NR1, or CR1R2;
• wherein, R1 and R2 are independently selected from H, halogen, substituted or unsubstituted C1-C8 alkyl and heteroalkyl, substituted or unsubstituted C3-C6 cycloalkyl and heterocycloalkyl;
• and R1 and R2 can be joined to form a ring;
• Y1, Y2, and Y3 are independently selected from N, CH, or CR1;
• R3 is Ar or
• wherein La is CH2, O, NH, or S;
• Ar is a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl;
• R4 and R5 are independently selected from H, substituted or unsubstituted C1-C8 alkyl;
• and
• G is
• where
• (a) R7 and R8 are H;
• R6 is H, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 heteroalkyl, C1-C8 alkylaminoalkyl, C1-C8 hydroxyalkylaminoalkyl, C1-C8 alkoxyalkylaminoalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted C1-C8 alkyl C3-C6 cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted C2-C8 heterocycloalkyl, substituted or unsubstituted heteroaryl, C1-C8 alkylethers, or C1-C8 alkylamides;
• (b) R6 and R8 are H;
• R7 is H, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 heteroalkyl, C1-C8 alkylaminoalkyl, C1-C8 hydroxyalkylaminoalkyl, C1-C8 alkoxyalkylaminoalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted C1-C8 alkyl C3-C6 cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted C2-C8 heterocycloalkyl, substituted or unsubstituted heteroaryl, C1-C8 alkylethers, or C1-C8 alkylamides;
• or
• (c) R7 and R8 taken together form a bond;
• R6 is substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 heteroalkyl, C1-C8 alkylaminoalkyl, C1-C8 hydroxyalkylaminoalkyl, C1-C8 alkoxyalkylaminoalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted C1-C8 alkyl C3-C6 cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted C2-C8 heterocycloalkyl, substituted or unsubstituted heteroaryl, C1-C8 alkylethers, or C1-C8 alkylamides, or;
• G is
• where R6 is H, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 heteroalkyl, C1-C8 alkylaminoalkyl, C1-C8 hydroxyalkylaminoalkyl, C1-C8 alkoxyalkylaminoalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted C1-C8 alkyl C3-C6 cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted C2-C8 heterocycloalkyl, substituted or unsubstituted heteroaryl, C1-C8 alkylethers, or C1-C8 alkylamides;
• wherein the condition associated with Bruton's Tyrosine Kinase (“BTK”) is myelofibrosis, acute myelogenous leukemia (AML), acute lymphotic leukemia (ALL), or chrinoc lymphocytic leukemia (CLL).